Imaging strategy for early ovarian cancer: Characterization of adnexal masses with conventional and advanced imaging techniques

Radiographics

Volumn 32, Issue 6, 2012, Pages 1751-1773

  Mohaghegh, Pegah ^a   Rockall, Andrea G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ARTICLE; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; FEMALE; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; PATHOLOGY;

CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; OVARIAN NEOPLASMS; ULTRASONOGRAPHY;

EID: 84867618810     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.326125520     Document Type: Article

References (51)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2: Cancer Incidence and Mortality Worldwide. IARC Cancerbase No.10. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr/. Published 2010. Accessed January 20, 2012.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
3. Kosary CL. Cancer of the Ovary. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph. Cancer Survival Among Adults: U.S. SEER Program, 1988-2001-Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, Md; 2007. http://seer.cancer.gov/publications/survival/surv_ovary.pdf. Published 2007. Accessed November 3, 2012.
4. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70(2): 209-262.
5. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Ovary and primary peritoneal carcinoma. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. New York, NY: Springer-Verlag, 2010; 419-428.
6. Cancer Research UK. Ovarian cancer survival statis-tics: March 2011. http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/#trends. Published 2011. Accessed January 20, 2012.
7. Office for National Statistics. Cancer survival in England: patients diagnosed 2005-2009 and followed up to 2010-November 2011. http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-survival-rates/2005-2009-followed-up-to-2010/summary-cancer-survival-2005-2009-followed-up-to-2010.html. Published 2011. Accessed January 20, 2012.
8. SEER. SEER Cancer Statistics Review: 1975-2008. http://seer.cancer.gov/csr/1975_2008/browse_csr.php?section = 21&page = sect_21_table.09.html. Published 2011. Accessed November 3, 2012.
9. Ellenson LH, Pirog EC. Female genital tract. In: Kumar V, Abbas AK, Aster J, Fausto N, eds. Robbins and Cotran pathologic basis of disease. Philadelphia, Pa: Elsevier Saunders, 2010; 1005-1064.
10. Link CJ Jr, Reed E, Sarosy G, Kohn EC. Borderline ovarian tumors. Am J Med 1996;101(2):217-225.
11. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19(1):58-64.
12. Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2010;256(3):943-954.
13. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25(20):2873-2883.
14. Bazot M, Nassar-Slaba J, Thomassin-Naggara I, Cortez A, Uzan S, Daraï E. MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors: correlation with final histology. Eur Radiol 2006;16(12):2687-2699.
15. Kokka F, Singh N, Reynolds K, et al. The accuracy of frozen section diagnosis in apparent early ovarian cancer: results from a UK centre. Histopathology 2009;55(6):756-758.
16. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205(4):358. e1-e6.
17. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20 (12):2496-2506.
18. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21(10 Suppl):206s-210s.
19. Urban N, Thorpe JD, Bergan LA, et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011;103(21): 1630-1634.
20. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57(11):1534-1544.
21. Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 2001;184(2):48-54.
22. Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998;208(1):103-110.
23. Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008;31(6): 681-690.
24. Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian masses: a meta-analysis. Radiology 2000;217(3):803-811.
25. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97(10):922-929.
26. Chia YN, Marsden DE, Robertson G, Hacker NF. Triage of ovarian masses. Aust N Z J Obstet Gynaecol 2008;48(3):322-328.
27. Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology 2010;257(1):144-150.
28. Rockall AG, Cross S, Flanagan S, Moore E, Avril N. The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging 2012;12:49-65.
29. Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005;60(3): 340-348.
30. Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization-meta-analysis and Bayesian a nalysis. Radiology 2005;236(1):85-94.
31. Thomassin-Naggara I, Daraï E, Cuenod CA, Rouzier R, Callard P, Bazot M. Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging 2008;28(1):111-120.
32. Yamashita Y, Hatanaka Y, Torashima M, Takahashi M, Miyazaki K, Okamura H. Characterization of sonographically indeterminate ovarian tumors with MR imaging: a logistic regression analysis. Acta Radiol 1997;38(4 Pt 1):572-577.
33. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology 2000;214(1):39-46.
34. Sohaib SA, Sahdev A, Van Trappen P, Jacobs IJ, Reznek RH. Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentgenol 2003; 180(5):1297-1304.
35. Bent CL, Sahdev A, Rockall AG, Singh N, Sohaib SA, Reznek RH. MRI appearances of borderline ovarian tumours. Clin Radiol 2009;64(4):430-438.
36. Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A. Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Eur Radiol 2010;20(9):2176-2183.
37. Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol 2012;22(4):880-890.
38. Thomassin-Naggara I, Balvay D, Cuenod CA, Daraï E, Marsault C, Bazot M. Dynamic contrast-enhanced MR imaging to assess physiologic variations of myometrial perfusion. Eur Radiol 2010;20(4): 984-994.
39. Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 2008;248(1):148-159.
40. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006;118(4):879-888.
41. Bagley RG, Weber W, Rouleau C, Teicher BA. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res 2005;65(21):9741-9750.
42. Priest AN, Gill AB, Kataoka M, et al. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 2010;63(4):1044-1049.
43. Thomassin-Naggara I, Balvay D, Aubert E, et al. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol 2012;22(4):738-745.
44. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92(9):1599-1610.
45. Fujii S, Matsusue E, Kanasaki Y, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 2008;18(1):18-23.
46. Sala E, Priest AN, Kataoka M, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla-technical development. Eur Radiol 2010;20(2):491-496.
47. Nakayama T, Yoshimitsu K, Irie H, et al. Diffusion-weighted echo-planar MR imaging and ADC mapping in the differential diagnosis of ovarian cystic masses: usefulness of detecting keratinoid substances in mature cystic teratomas. J Magn Reson Imaging 2005;22(2):271-278.
48. Chilla B, Hauser N, Singer G, Trippel M, Froehlich JM, Kubik-Huch RA. Indeterminate adnexal masses at ultrasound: effect of MRI imaging findings on diagnostic thinking and therapeutic decisions. Eur Radiol 2011;21(6):1301-1310.
49. Fujii S, Kakite S, Nishihara K, et al. Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging 2008;28(5):1149-1156.
50. Thomassin-Naggara I, Daraï E, Cuenod CA, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol 2009;19(6):1544-1552.
51. Thomassin-Naggara I, Toussaint I, Perrot N, et al. Characterization of complex adnexal masses: value of adding perfusion-and diffusion-weighted MR imaging to conventional MR imaging. Radiology 2011;258(3):793-803.